Celebrity Designer And ADHD Spokesperson Ty Pennington Partners With Shire To Announce The Launch Of VYVANSEв„ў For Adult ADHD Treatment

Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has launched VYVANSEв„ў (lisdexamfetamine dimesylate) for the treatment of adults with Attention Deficit Hyperactivity Disorder (ADHD). This launch follows the recent FDA approval of VYVANSE to treat ADHD in the adult population. VYVANSE is now available in U.S. pharmacies nationwide in six once-daily dosage strengths.